Details of the Drug Formulations

General Information of Drug (ID: DM749I3)

• Drug Name: Ubrogepant Drug Info
• Synonyms: 1374248-77-7; UNII-AD0O8X2QJR; MK-1602; AD0O8X2QJR; Ubrogepant [USAN:INN]; Ubrogepant (USAN/INN); SCHEMBL3698428; CHEMBL2364638; GTPL10176; DTXSID00160178; DDOOFTLHJSMHLN-ZQHRPCGSSA-N; MK1602; ZINC95598454; SB19741; HY-12366; CS-0011109; D10673; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Approved	[1]

• Cross-matching ID:
  PubChem CID: 68748835
  CAS Number: 1374248-77-7
  TTD ID: D07GXR
  ACDINA ID: D01511

Full List of Drug Formulations Containing This Drug

Ubrogepant 100 mg tablet

Company	Formulation ID	FDA Description
Allergan	F24156	Colloidal Silicon Dioxide; Croscarmellose Sodium; Mannitol; Microcrystalline Cellulose; Polyvinylpyrrolidone Vinyl Acetate Copolymer; Sodium Chloride; Sodium Stearyl Fumarate; Vitamin E Polyethylene Glycol Succinate

Ubrogepant 50 mg tablet

Company	Formulation ID	FDA Description
Allergan	F24157	Colloidal Silicon Dioxide; Croscarmellose Sodium; Mannitol; Microcrystalline Cellulose; Polyvinylpyrrolidone Vinyl Acetate Copolymer; Sodium Chloride; Sodium Stearyl Fumarate; Vitamin E Polyethylene Glycol Succinate

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019